Trastuzumab and patuzumab are recombinant humanized monoclonal antibodies that target HER2 to prevent cancer growth, and the TANDEM, EGF30008, and eLEcTRA studies have demonstrated the value of single-targeted endocrine therapies (67–69). The gene discussed is ERBB2; the disease is cancer.